DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study In Patients With Kidney Cancer Treated With Sutent

Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Advanced or Metastatic Renal Cell Carcinoma; Renal Cancer

Intervention: Sutent (Drug)

Phase: N/A

Status: Completed

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Summary

Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.

Clinical Details

Official title: Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With Sutent

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Increased knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib

Secondary outcome:

Dose modifications

Incidence of new diagnosed hypertension

Incidence of new diagnosed hypothyroidism

Safety of sunitinib malate in "real-life" setting

Efficacy of sunitinib malate in "real-life" setting

Detailed description: Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Consecutive patients with advanced or metastatic renal cell carcinoma, that are

indicated for 1st or 2nd line anticancer therapy Exclusion Criteria:

- Hypersensitivity to sunitinib malate or to any of the excipients

- Any other contraindication to the use of sunitinib malate (based on decision of the

treating physician).

Locations and Contacts

Pfizer Investigational Site, Banska Bystrica 975 17, Slovakia

Pfizer Investigational Site, Bojnice 972 01, Slovakia

Pfizer Investigational Site, Bratislava 812 50, Slovakia

Pfizer Investigational Site, Bratislava 833 10, Slovakia

Pfizer Investigational Site, Kosice 043 91, Slovakia

Pfizer Investigational Site, Michalovce 071 01, Slovakia

Pfizer Investigational Site, Nitra 949 01, Slovakia

Pfizer Investigational Site, Poprad 058 01, Slovakia

Pfizer Investigational Site, Presov 081 81, Slovakia

Pfizer Investigational Site, Ruzomberok 034 26, Slovakia

Pfizer Investigational Site, Trebisov 075 01, Slovakia

Pfizer Investigational Site, Trencin 911 71, Slovakia

Pfizer Investigational Site, Trnava 917 75, Slovakia

Pfizer Investigational Site, Zilina 012 07, Slovakia

Additional Information

To obtain contact information for a study center near you, click here.

Starting date: May 2009
Last updated: November 7, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017